Medication info
Dapljinmet Controlled-Release Tablets 10/500 mg (Dapagliflozin Propanediol Hydrate, Metformin Hydrochloride)

Dapljinmet Controlled-Release Tablets 10/500 mg (Dapagliflozin Propanediol Hydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletDapagliflozin Propanediol Hydrate›12.3mg / 1 tablet
Manufacturer / importer
Dongkuk Pharmaceutical Co., Ltd.
Appearance
Pink rectangular controlled-release film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP) x 5], 30 tablets/bottle
Approval status
Active

MFDS item code 202302574 · Approved 2023.08.30 · Insurance code 653405450

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior experience of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse reactions to metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When converting from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering agents. Because changes may cause alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes mellitus should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more but less than 60 mL/min/1.73 m2, and with no other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine must be discontinued immediately. Renal function should be evaluated every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Manufacturer
Dongkuk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Failure of blood sugar control
  • type 2 diabetes
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used in combination with dietary therapy and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. Particularly in patients with inadequate blood sugar control who have cardiovascular disease or risk factors, caution should be taken considering the possibility of cardiovascular events. This medication assists in improving blood sugar levels and managing cardiovascular risks.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior experience of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse reactions to metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When converting from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering agents. Because changes may cause alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes mellitus should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more but less than 60 mL/min/1.73 m2, and with no other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine must be discontinued immediately. Renal function should be evaluated every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This medication is used for the treatment of diabetes and contains two components that lower blood sugar. When taking this medication, it is essential to check that kidney function is normal. Patients with severely impaired kidney function or acute renal failure should not use it. Additionally, patients in states of dehydration, severe infections, cardiovascular issues, or acute myocardial infarction should avoid this medication. Pregnant or nursing women should not use this medication, and patients with lactose intolerance should also avoid it. The risk of hypoglycemia may increase when this medication is used in combination with insulin or sulfonylureas, hence caution is needed when used together, and insulin dosages may need adjustment if necessary. This medication can cause a decrease in blood volume or low blood pressure, so especially for the elderly or patients taking diuretics, blood pressure and fluid status should be monitored closely. During treatment, genital infections or urinary tract infections may occur, so if symptoms of infection appear, immediate consultation with a healthcare professional is advised. Furthermore, this medication carries a risk of serious metabolic complications such as lactic acidosis and ketoacidosis; thus, if symptoms such as fatigue, shortness of breath, or abdominal pain occur, immediate medical attention should be sought. It is advisable to avoid alcohol consumption while taking this medication and to temporarily discontinue it prior to surgery or contrast examinations, resuming only after verifying kidney function. Vitamin B12 deficiency may occur, so regular monitoring of serum vitamin B12 levels is required with prolonged use. Finally, special caution is needed for children and elderly patients over 80 years old, as the safety and efficacy of this medication have not been sufficiently established.

Side effects

  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • fluid volume depletion
  • thirst
  • diabetic ketoacidosis
  • dizziness
Show 82 more
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated blood creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • vitamin B12 deficiency
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • malignant neoplasm of the lung
  • uterine fibroid
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbances
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • elevated blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • chondromalacia
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is advisable to keep it at room temperature, between 1 to 30 degrees Celsius. This helps maintain the efficacy of the medication.

Appearance and packaging

Appearance

Pink rectangular controlled-release film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP) x 5], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.